Table 3.
Comparison of the baseline characteristics of the SC combined with TLC group and TLC group before the intervention.
| SC combined with TLC group | TLC group | P | |
|---|---|---|---|
| Age, years | 42.7 ± 8.9 | 45.49 ± 9.6 | 0.004 |
| Male patients, n (%) | 108 (93.9) | 125 (80.6) | 0.002 |
| BMI, kg/m2 | 25.21 ± 3.2 | 24.2 ± 3.1 | 0.629 |
| Waist circumference, cm | 87.38 ± 16.1 | 85.2 ± 7.4 | 0.216 |
| Hip circumference, cm | 96.74 ± 5.6 | 95.12 ± 5.4 | 0.389 |
| ALT, U/L | 46 (32–68) | 34 (23–47) | < 0.001 |
| AST, U/L | 37 (27–53) | 30 (24–39) | 0.001 |
| Fasting glucose, mmol/L | 5.67 ± 1.3 | 5.90 ± 1.9 | 0.881 |
| TG, mmol/L | 1.76 ± 1.2 | 1.55 ± 1.0 | 0.417 |
| Cholesterol, mmol/L | 4.18 ± 1.2 | 4.17 ± 0.8 | 0.836 |
| HDL-C, mmol/L | 1.40 ± 1.2 | 1.21 ± 0.4 | 0.546 |
| LDL-C, mmol/L | 2.43 ± 0.8 | 2.42 ± 0.73 | 0.983 |
| ALB, g/L | 45.83 ± 5.3 | 45.30 ± 4.1 | 0.281 |
| GLB, g/L | 31.37 ± 9.9 | 31.2 ± 6.4 | 0.127 |
| TB, μmol/L | 22.8 ± 38.0 | 19.17 ± 13.4 | 0.297 |
| DB, μmol/L | 9.3 ± 26.8 | 6.37 ± 7.1 | 0.815 |
| GGT, U/L | 32 (19–58) | 28 (17–46) | 0.117 |
| ALP, U/L | 78 (62–101) | 75 (65–99) | 0.811 |
| Platelet × 109/L | 118 (81–169) | 108 (72–168) | 0.678 |
| Undetectable HBV DNA, n (%) | 90 (78.3) | 122 (78.7) | 0.929 |
| HBeAg-negative, n (%) | 79 (68.7) | 108 (69.7) | 0.469 |
| NAs treatment, n (%) | 70 (60.9) | 101 (65.2) | 0.449 |
| LSM, kPa | 12.31 ± 8.0 | 11.48 ± 8.2 | 0.279 |
| CAP, dB/m | 282.11 ± 37.30 | 272.43 ± 28.20 | 0.115 |
BMI body mass index, ALT alanine aminotransferase, AST aspartate aminotransferase, TB total bilirubin, DB direct bilirubin, TG triacylglycerol, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, GGT gamma glutamyltransferase, ALP alkaline phosphatase, LSM liver stiffness measurement, CAP controlled attenuation parameter.